· Investment Strategies · 4 sources
Xapien’s $56M Series B: Spectrum Bets on Always-On Due Diligence
Spectrum Equity led Xapien’s $56 million Series B on September 11, 2026. The AI due-diligence platform claims 350%+ ARR growth over 24 months, 350 clients in 15 countries, and half of revenue already from the U.S.
Editorial team
Xapien raised $56 million Series B financing announced September 11, 2026, led by Spectrum Equity, with existing investor YFM Equity Partners returning. Axios labels the round Series B; the company calls it a growth investment. Valuation was not disclosed. Use of proceeds: expand the U.S. presence (already 50% of revenue), grow the Boston office, and relocate the CEO and other leaders (company, Axios).
Spine: Compliance teams still ration diligence to a fraction of counterparties. Xapien is selling full coverage plus continuous monitoring — and Spectrum’s World-Check / Verafin pattern recognition is the investor tell.
Key facts
- Company
- Xapien (xapien.com) — London-founded, Boston expansion
- Round
- $56M Series B (Axios) / growth investment (company)
- Lead
- Spectrum Equity (Adam Margolin quoted)
- Returning
- YFM Equity Partners (led 2024 Series A)
- Traction (company)
- 350%+ ARR growth over 24 months; 350 clients/partners in 15 countries; U.S. 50% of revenue
- Named logos
- Greenberg Traurig, ABB, Dow Jones Risk & Compliance, KPMG
- Prior
- $10M Series A / £8M (July 2024) led by YFM; total then $17.8M
- Valuation
- Not disclosed
Who uses the product — and for what job
Users: compliance, legal, and procurement teams inside multinational corporations, law firms, private banks, universities, nonprofits, and professional-services firms that automate research for clients.
Job: turn open-web + registry + sanctions + media into a sourced, auditable counterparty report in minutes, then (via Xapien Live beta) keep watching risk after onboarding.
Company claim: clients report 90% of onboarding cases can be fully automated so analysts focus on complex/high-risk files. Treat as customer-reported, not audited. The company cites industry bandwidth pain — only 30% of organizations say they can assess even half of relationships — as the coverage gap it sells into.
Why now
- Agent-era business moves faster than static KYC packets; one-off onboarding checks leave unmonitored third-party risk.
- Spectrum’s risk-tech portfolio (World-Check, Verafin, and peers named in the release) signals a category buyer who knows compliance distribution.
- U.S. already half of revenue — the raise is a relocation / go-to-market bet, not a first beachhead.
Why Spectrum — portfolio fit
Spectrum Equity specializes in growth software with risk-and-compliance DNA. Leading $56M after YFM’s Series A fits a category-standard thesis: automation that still clears audit bars. Spectrum Equity and YFM have no /fund/ pages here — editorial only.
YFM returning is continuity capital, not a new logo hunt.
Competitive map
| Approach | Tradeoff |
|---|---|
| Manual research / Big Four projects | Depth; rationed coverage |
| Legacy screening lists alone | Fast hits; weak narrative risk |
| Generic LLM research | Speed; weak audit trail / entity resolution |
| Xapien AI + continuous Live | Throughput + monitoring; must prove accuracy at scale |
What is not proven
- Valuation, absolute ARR, and churn.
- How often “90% automated” holds outside named design partners.
- Whether Live exits beta with the same trust bar as point-in-time reports.
Practical takeaway
- Founders (RegTech): Sell coverage × continuous monitoring, not “AI that writes memos.”
- Investors: Diligence false-positive rates and analyst time saved vs. legacy stacks.
- Operators: Relevant if you still sample counterparties because bandwidth — not appetite — is the constraint.
Follow Venture Capital Tracker on Google
Add VCT as a preferred source to see more of our venture-capital reporting in Google Search.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.